Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation.
Giorgio Liguori, Antonino Parlato, Alessandro Sanduzzi Zamparelli, Patrizia Belfiore, Francesca Gall��, Valeria Di Onofrio, Carla Riganti, Bruno Zamparelli, Societ�� Italiana di Health Horizon Scanning (SIHHS)
Author Information
Giorgio Liguori: Chair of Hygiene and Epidemiology; Department of Studies of Institutions and Territorial Systems; University of Naples "Parthenope"; Naples, Italy.
Antonino Parlato: Complex Operative Unit "Epidemiology and Prevention"; Local Health Authority NA2 Nord; Naples, Italy.
Alessandro Sanduzzi Zamparelli: Complex Operative Unit of the hospital Monaldi "Second Division of Respiratory Diseases"; University of Naples Federico II; Naples, Italy.
Patrizia Belfiore: Chair of Hygiene and Epidemiology; Department of Studies of Institutions and Territorial Systems; University of Naples "Parthenope"; Naples, Italy.
Francesca Gall��: Chair of Hygiene and Epidemiology; Department of Studies of Institutions and Territorial Systems; University of Naples "Parthenope"; Naples, Italy.
Valeria Di Onofrio: Chair of Hygiene and Epidemiology; Department of Studies of Institutions and Territorial Systems; University of Naples "Parthenope"; Naples, Italy.
Carla Riganti: General Hospital "Federico II"-Institutional Relationships Hospitals and Local Health Authorities of Campania Region; Naples, Italy.
Bruno Zamparelli: "SS Annunziata"-"Santobono-Pausilipon" Hospital; Naples, Italy.
Pneumococcal pneumonia has a high clinical burden in terms of morbidity, mortality and hospitalization rate, with heavy implications for worldwide health systems. In particular, higher incidence and mortality rates of community-acquired pneumonia (CAP) cases, with related costs, are registered among elderly. This study aimed to an economic evaluation about the immunization with PCV13 in the adult population in Campania region, South Italy. For this purpose we performed, considering a period of 5 y, a budget impact analysis (BIA) and a cost-effectiveness analysis which considered 2 scenarios of immunization compared with lack of immunization for 2 targeted cohorts: first, the high risk subjects aged 50-79 y, and second the high risk individuals aged 50-64 y, together with all those aged 65 y. Regarding the first group, the decrease of pneumonia could give savings equal to ���29,005,660, while the immunization of the second cohort could allow savings equal to ���10,006,017. The economic evaluation of pneumococcal vaccine for adult groups represents an essential instrument to support health policies. This study showed that both hypothesized immunization strategies could produce savings. Obtained results support the use of pneumococcal conjugate vaccine for adults. This strategy could represent a sustainable and savings-producer health policy.
